SpringerLink
Log in

Current and future perspectives on the TARGET system: the registration system for Glivec® established by the JSH

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Since hematology is a highly specialized field, an individual physician may not have much direct treatment experience with a given disease. Therefore, the Japanese Society of Hematology (JSH) has discussed establishing a registry of hematologic disorders, in order to contribute to improving the quality of treatments and clinical outcomes in this field. As a first step, the Timely and Appropriate Registration System for GLIVEC Therapy (TARGET), a registration system for chronic myeloid leukemia (CML) patients treated with imatinib, was established in October 2003. We present the preliminary results of the first 4 years’ experience with this system. CML patients treated with imatinib in Japan were registered through the website and the patient’s clinical course, including parameters and events like imatinib dose, blood counts, adverse events, and efficacy were recorded in months 1, 3, 6, 9, and 12 and then every 6 months thereafter. By September 2007, 862 patients from 176 hospitals were registered. Follow-up period was 0–54 months, and 127 patients were followed-up for more than 36 months. Based on these cumulative data, present imatinib treatment trends were analyzed and safety and efficacy were compared with international trial data.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Cancer Incidence in Five Countries, vol VIII, Parkin DM, et al., eds. IARC Press, Lyon, 2002.

  2. O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004. doi:10.1056/NEJMoa022457.

    Article  PubMed  Google Scholar 

  3. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17. doi:10.1056/NEJMoa062867.

    Article  CAS  PubMed  Google Scholar 

  4. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or intereferon α plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423–32. doi:10.1056/NEJMoa030513.

    Article  CAS  PubMed  Google Scholar 

  5. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12:908–16. doi:10.1038/nm1446.

    Article  PubMed  Google Scholar 

  6. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–42. doi:10.1056/NEJM200104053441402.

    Article  CAS  PubMed  Google Scholar 

  7. Kantarjian HM, Talpatz M, Giles F, O’Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145:913–23.

    Article  PubMed  Google Scholar 

  8. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:867–80. doi:10.1126/science.1062538.

    Article  Google Scholar 

  9. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542–51. doi:10.1056/NEJMoa055104.

    Article  PubMed  Google Scholar 

  10. Talpatz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–41. doi:10.1056/NEJMoa055229.

    Article  Google Scholar 

  11. Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007;107:497–9. doi:10.1182/blood-2006-07-035493.

    Article  Google Scholar 

  12. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2006 (Epub ahead of print).

Download references

Acknowledgments

The Hematological Disease Registration Committee members are grateful to the hematologists from around Japan for their cooperation with the TARGET system and registration of cases.

Author information

Authors and Affiliations

  1. Department of Hematology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan

    Masahiro Kizaki

  2. Division of Hematology, Keio University School of Medicine, Tokyo, Japan

    Shinichiro Okamoto

  3. First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan

    Tetsuzo Tauchi

  4. Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    Hideo Tanaka

  5. Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

    Mitsune Tanimoto

  6. Division of Hematology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan

    Koiti Inokuchi

  7. Hematology Division, Department of Medicine, Hyogo Cancer Center, Hyogo, Japan

    Tohru Murayama

  8. Department of Hematology, Oita Prefectural Hospital, Oita, Japan

    Yoshio Saburi

  9. Clinical Hematology and Clinical Diagnosis, Graduate School of Medicine, Osaka City University, Osaka, Japan

    Masayuki Hino

  10. Department of Hematology, Osaka Red Cross Hospital, Osaka, Japan

    Mitsuru Tsudo

  11. Department of Hematology, NTT Japan Kyushu Hospital, Kumamoto, Japan

    Taizo Shimomura

  12. Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan

    Yasushi Isobe

Authors
  1. Masahiro Kizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shinichiro Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tetsuzo Tauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hideo Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mitsune Tanimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Koiti Inokuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tohru Murayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoshio Saburi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masayuki Hino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mitsuru Tsudo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Taizo Shimomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yasushi Isobe
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

and the TARGET Investigators

Corresponding author

Correspondence to Masahiro Kizaki.

Additional information

The part of content in this article was presented in the Joint Annual Conference of the 68th Japanese Society of Hematology (JSH) and the 48th Japanese Society of Clinical Hematology (JSCH) in Fukuoka (Japan) at 7 October 2006.

Other participants in the TARGET system are listed in the Appendix.

Appendix

Appendix

The following 428 investigators participated and registered patients for the TARGET system: (Hokkaido) S. Andoh, N. Fuse, Y. Hirata, T. Ishihara, Y. Iuchi, H. Iwasaki, K. Kahata, Y. Kanisawa, M. Kida, H. Kuroda, M. Kurosawa, M. Maemori, N. Masauji, T. Minami, Y. Nagamachi, H. Sakai, M. Shindoh, F. Takahashi, Y. Tsutsumi, S. Yamamoto (Iwate) S. Hoshi, Y. Narigasawa, N. Sakai, A. Satoh, Y. Wano (Miyagi) A. Miura, Y. Saitoh, T. Shishido (Akita) A. Chuhbachi, N. Fujishima, R. Inaba, Y. Kameoka, J. Kuroki, I. Miura, M. Motegi, H. Niitsu, N. Takahashi, A. Watanabe (Yamagata) S. Hamanaka, Y. Izumiguchi, H. Kumagai, E. Ohmoto, S. Satoh (Fukushima) K. Nakamura, Y. Shiga (Ibaraki) T. Itoh, T. Komeno (Tochigi) Y. Furukawa, I. Oh, Y. Ohshima, M. Yatabe (Gunma) A. Handa, H. Handa, H. Irisawa, T. Mitsui, S. Miyawaki, Y. Miyazawa, K. Murayama, Y. Ogawa, H. Ogura, A. Saitoh, S. Shimano, N. Tsukamoto, A. Yamane (Saitama) Y. Habu, T. Higuchi, K. Kogawa, J. Nishida, K. Okamoto, R. Watanabe, F. Yagasaki, Y. Yamamoto (Chiba) N. Aotsuka, T. Katayama, K. Kikuno, C. Nakaseko, M. Nakata, T. Nonaka, H. Tanaka, N. Yokose (Tokyo) O. Asai, S. Chiba, K. Dan, T. Fukuda, T. Funatsu, Y. Harada, Y. Hattori, N. Horikoshi, M. Inami, K. Inokuchi, T. Kaneko, K. Kitano, M. Kizaki, Y. Kobayashi, K. Kogure, K. Koh, Y. Komeno, K. Kumano, Y. Kuriyama, M. Maeda, A. Manabe, S. Masuda, M. Matsubara, Y. Miyakawa, D. Mizuchi, Y. Mori, T. Motoji, S. Motomura, A. Mutoh, Y. Mutoh, M. Nagasawa, K. Nakamura, N. Nakamura, Y. Nakamura, Y. Nanya, Y. Nehashi, E. Nitta, E. Oda, A. Ohara, F. Ohba, K. Ohshima, K. Ohyashiki, S. Okamoto, S. Okuda, K. Oshimi, Y. Sameshima, N. Satoh, H. Shimada, S. Sunaga, K. Suzuki, T. Suzuki, K. Tadika, H. Takahashi, H. Takano, T. Tauchi, K. Tobinai, S. Tohda, D. Tomizawa, H. Uchida, K. Uchimaru, N. Uemura, H. Ueno, M. Yamaguchi, M. Yamamoto, Y. Yokoyama, M. Yoshida, T. Yoshida, K. Yoshinaga (Kanagawa) S. Gomi, H. Harada, H. Harano, A. Ieda, K. Isoyama, T. Kakimoto, T. Kumagai, M. Kurimoto, H. Miyashita, K. Miyazaki, H. Mori, T. Nagao, T. Nakazato, H. Nishida, M. Oki, Y. Satoh, K. Tabuchi, M. Tanaka, T. Togano, K. Tsuboi, H. Yabe, M. Yabe, K. Yamamoto, E. Yamazaki (Niigata) M. Fujiwara, T. Furukawa, T. Hirose, Y. Seki, T. Yano (Toyama) K. Kyohda, S. Matano, N. Sugimori, T. Tanaka, Y. Terasaki (Ishikawa) T. Chuhjou, T. Fukushima, Y. Kondoh, S. Nakao, K. Ohhata, S. Ohtake, C. Sugimori, M. Yamaguchi, S. Yamanaka, H. Yamazaki, M. Yamazaki, T. Yanase (Fukui) H. Takemura, A. Tanizawa (Yamanashi) T. Inukai, N. Komatsu (Nagano) K. Hirabayashi, M. Hirakata, N. Ichikawa, F. Ishida, H. Kodaira, Y. Kohara, A. Oguchi, S. Takakura, M. Ueno, M. Yotsumoto (Gifu) K. Fukuno, T. Itoh, M. Murayama (Shizuoka) K. Kawakami, M. Koike, N. Mochizuki, Y. Mochizuki, K. Naitoh, Y. Nakaboh, K. Nara, K. Ohnishi, K. Okinaka, N. Sahara, K. Shigeno, S. Takemura, T. Tobita (Aichi) N. Emi, Y. Inamoto, T. Ino, Y. Ishikawa, K. Matsumoto, T. Murase, E. Nagura, K. Ohbayashi, H. Suzuki, S. Tamori, H. Toyozumi, A. Wakita (Mie) T. Tsukada (Shiga) S. Araki, H.Kamesaki, K. Kitou, T. Kitou, S. Nakano, T. Ohno, T. Taga, S. Tanaka (Kyoto) T. Hirata, S. Horiike, H. Kawabata, T. Kitano, T. Kitawaki, Y. Kobayashi, T. Maekawa, K. Miyaoka, S. Murakami, N. Nakazawa, T. Shindoh, K. Ueda (Osaka) N. Arima, N. Dohmae, M. Fujimoto, J. Fujita, Y. Furukawa, S. Hara, T. Hasuike, M. Higashishiba, M. Hino, M. Hishizawa, M. Inoue, N. Iwata, H. Kaneko, Y. Kataoka, M. Kawamura, Y. Kin, Y. Kishimoto, Y. Konaka, J. Kuyama, T. Matsubuchi, N. Matsumoto, I. Matsumura, Y. Miura, M. Nishizawa, N. Ohhara, H. Ohta, N. Sakata, H. Shibayama, T. Sohma, H. Sugiyama, S. Tokimasa, M. Tsuhdou, N. Uoshima, M. Watanabe, K. Zen (Hyogo) Y. Adachi, H. Gomyoh, A. Hayakawa, Y. Hiramatsu, J. Kanda, M. Kataoka, H. Kawamoto, T. Matsumura, M. Misawa, I. Mizuno, T. Murayama, N. Oku, A. Shimasaki, T. Tahara, Y. Tokumine, I. Usami, S. Yoshihara (Nara) T. Hayashi, B. Higuchi, T. Kishimoto, Y. Maesako, N. Shintaku, H. Tanaka (Wakayama) M. Kobayashi, R. Sakaguchi (Tottori) T. Tanaka (Shimane) Y. Maniwa, M. Nishikori, T. Takahashi, M. Tsumori (Okayama) N. Fujii, D. Hashimoto, K. Ikeda, F. Ishimaru, K. Kobayashi, Y. Maeda, K. Matsuoka, T. Miyamura, Y. Sakoda, K. Shinagawa, H. Sugiyama, K. Sunami, M. Takeuchi, S. Tateishi (Hiroshima) K. Hamamoto, F. Imanaka, T. Masunari, A. Miyata, H. Tanaka (Yamaguchi) T. Takahashi, T. Wada (Tokushima) T. Gotoh, T. Shigekiyo, M. Shinohara (Kagawa) M. Ide, Y. Kawachi, Y. Kubota, H. Takimoto, T. Taoka, M. Waki (Ehime) T. Azuma, M. Hamada, Y. Kimura, T. Kozuka, K. Kubo, T. Muta, K. Nakase, I. Sakai, J. Yamanouchi, M. Yasukawa, I. Yoshida (Kochi) M. Daibata, T. Ikezoe, K. Togitani (Fukuoka) Y. Abe, I. Che, T. Etoh, S. Hayashi, M. Higuchi, N. Hirase, R. Imamura, A. Iwashige, H. Johjima, Y. Koga, M. Misago, H. Morimoto, H. Nakayama, S. Okamura, T. Shibuya, A. Suminoe, J. Suzumiya, Y. Tachikawa, K. Takase, H. Takatsuki, K. Tamura, K. Tanaka, Y. Yamasaki (Saga) T. Hisatomi, M. Sano, E. Sueoka (Nagasaki) A. Kamitamari, E. Matsuo, Y. Moriuchi, Y. Takasaki, S. Tominaga, S. Yoshida (Kumamoto) N. Asoh, M. Imamura, M. Kawakita, T. Sawatari, T. Shimomura, H. Suzushima (Oita) T. Andoh, K. Gotoh, T. Hosokawa, M. Iwahashi, J. Nishimura, E. Ohno, E. Ohtsuka, Y. Saburi, M. Shiratsuchi (Miyazaki) H. Kawano, H. Matsuoka, Y. Sugio, K. Yamashita (Kagoshima) T. Makino, M. Ohtsuka, A. Utsunomiya (Okinawa) Y. Asakura, K. Harano, N. Hyakuna, M. Masuda, K. Ohshiro, N. Taira, T. Tomoyose, M. Yoshida.

About this article

Cite this article

Kizaki, M., Okamoto, S., Tauchi, T. et al. Current and future perspectives on the TARGET system: the registration system for Glivec® established by the JSH. Int J Hematol 88, 409–417 (2008). https://doi.org/10.1007/s12185-008-0186-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-008-0186-0

Keywords

Search

Navigation